HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood–tumor barrier penetration unlinked to a passive marker

BACKGROUND: Brain metastases of HER2+ breast cancer persist as a clinical challenge. Many therapeutics directed at human epidermal growth factor receptor 2 (HER2) are antibodies or antibody-drug conjugates (ADCs), and their permeability through the blood–tumor barrier (BTB) is poorly understood. We...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Gril, Brunilde, Wei, Debbie, Zimmer, Alexandra S, Robinson, Christina, Khan, Imran, Difilippantonio, Simone, Overstreet, Michael G, Steeg, Patricia S
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Basic and Translational Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7690367/
https://ncbi.nlm.nih.gov/pubmed/32386414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa118
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars